Genetic Polymorphism of Drug-Metabolizing Enzymes<i>CYP2C9</i>and<i>CYP2C19</i>in Moroccan Population

Afilal, Driss; Basselam, Mohamed Amine; Brakez, Zahra; Chouham, Said; Brehm, António; Izaabel, El Hassan

doi:10.1089/gtmb.2016.0304

Cited by 7 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of the CYP2C19*2 allele was 16.3% in the population from the Republic of Srpska in Bosnia and Herzegovina [43], and 13.1% in a Greek population [44]. In Moroccan population, the percentage of CYP2C19 *2, and *3 allele was 11.38%, and 0%, respectively [45], whereas 6%, and 0% in a Ghanaian population [46], 12.6% and 0.3% in the Egyptian population [47]. The percentage of CYP2C19*2, and *3 allele was 12.5%, and 0.6% respectively, in Iranian population [48], 13% and 3% in Lebanese population [49].…”

Section: Discussionmentioning

confidence: 92%

CYP2C19 loss-of-function is associated with increased risk of hypertension in a Hakka population: a case-control study

Cai

et al. 2023

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Genetic factors have a certain proportion in the risk factors of hypertension. The purpose was to investigate the relationship of cytochrome P450 2C19 (CYP2C19) polymorphisms with hypertension in Hakka population. Methods The study included 1,872 hypertensive patients and 1,110 controls. The genotypes of CYP2C19 rs4244285 and rs4986893 of all individuals were detected and analyzed. Results The genotype and allele distributions of CYP2C19 rs4244285 were significantly different between hypertension group and control group. The CYP2C19 *1/*1 genotype was the most predominant among the subjects (40.8%), followed by the CYP2C19 *1/*2 genotype (40.5%). The percentage of CYP2C19*1, *2, and *3 allele was 64.2%, 30.8%, and 5.0%, respectively. The proportion of intermediate metabolizers (IM) (49.3% vs. 42.9%), poor metabolizers (PM) (14.3% vs. 8.9%) (P < 0.001), and CYP2C19*2 allele (33.8% vs. 25.7%, P < 0.001) in hypertension group was significantly higher than that in control group. Multivariate logistic regression (adjusted for gender, age, smoking, and drinking) indicated that CYP2C19 *1/*2, *1/*3, and *2/*2 genotypes may increase susceptibility to hypertension. And the CYP2C19 IM genotype (IM vs. EM: OR 1.514, 95% CI: 1.291–1.775, P < 0.001), PM genotype (PM vs. EM: OR 2.120, 95% CI: 1.638–2.743, P < 0.001), IM + PM genotypes (IM + PM vs. EM: OR 1.617, 95% CI: 1.390–1.882, P < 0.001) may increase risk of hypertension. Conclusions CYP2C19 loss-of-function (IM, PM genotypes) is independent risk factor for hypertension susceptibility. Specifically, the risk genotypes include CYP2C19 *1/*2, *1/*3, and *2/*2.

show abstract

Section: Discussionmentioning

confidence: 92%

CYP2C19 loss-of-function is associated with increased risk of hypertension in a Hakka population: a case-control study

Cai

et al. 2023

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

“…22 The prevalence of CYP2C19 EM, IM, and PM phenotypes was 75.97%, 21.91%, and 2.21% in a Greek population. 23 In Moroccan population, the percentages of CYP2C19 EM, IM, and PM phenotypes was 83.45%, 14.14%, and 2.41%, respectively, 24 the percentages was 75.8%, 21.1%, and 3.1% in Lebanese population. 25 In the populations from Americas, the percentages of CYP2C19 EM, IM, and PM phenotypes were 85.3%, 13.6%, and 1.0%, respectively, in a Bolivian population, 26 71.1%, 14.2%, and 0.5% in a Nicaraguan Mestizo population.…”

Section: Discussionmentioning

confidence: 98%

Differences in the Proportion of CYP2C19 Loss-of-Function Between Cerebral Infarction and Coronary Artery Disease Patients

Shi¹,

Yang²,

Feng³

et al. 2023

IJGM

View full text Add to dashboard Cite

Background: Cytochrome P450 2C19 (CYP2C19) genotypes and metabolic phenotypes (extensive metabolizer (EM), intermediate metabolizer (IM), and poor metabolizer (PM)) are related to the metabolism of therapeutic drugs for cardiovascular and cerebrovascular diseases. This study aimed to investigate the differences of CYP2C19 gene polymorphism distribution between coronary artery disease (CAD) patients and cerebral infarction (CI) patients. Methods: We identified 413 CI patients, 509 CAD patients, and 241 CI+CAD patients from 2016 to 2020 and studied genotypes of CYP2C19 rs4986893 (636G>A) and rs4244285 (681G>A) polymorphisms using PCR-gene chip detection method. Differences in CYP2C19 genotypes and metabolic phenotypes between the groups were compared. To analyze the efficacy of CYP2C19 metabolic phenotypes in discriminating between cerebral infarction and coronary artery disease, multiple logistic regression analysis was conducted after adjusting for gender, age, smoking history, drinking history, hypertension, and diabetes. Results: There were significant differences in the distribution of CYP2C19 genotypes and metabolic phenotypes between CI and CAD patients. The results of multivariate logistic regression (adjusted for sex, age, smoking, drinking, hypertension, and diabetes) indicated that CYP2C19 IM phenotype (IM vs EM: OR 1.443, 95% CI: 1.086-1.918, P=0.011) and CYP2C19 IM+PM phenotype (IM or PM vs EM: OR 1.440, 95% CI: 1.100-1.885, P=0.008) may be indicators of CI from CAD. Conclusion: CYP2C19 EM metabolic phenotype was dominant in CAD patients, and CYP2C19 IM metabolic phenotype was dominant in CI patients. After adjusting for other confounding factors, patients with the CYP2C19 IM metabolic phenotype were more likely to develop CI than CAD.

show abstract

Association of CYP2C19*2/3 gene polymorphism with lung cancer in Moroccan population

et al. 2021

View full text Add to dashboard Cite

Genetic Polymorphism of Drug-Metabolizing EnzymesCYP2C9andCYP2C19in Moroccan Population

Cited by 7 publications

References 58 publications

CYP2C19 loss-of-function is associated with increased risk of hypertension in a Hakka population: a case-control study

CYP2C19 loss-of-function is associated with increased risk of hypertension in a Hakka population: a case-control study

Differences in the Proportion of CYP2C19 Loss-of-Function Between Cerebral Infarction and Coronary Artery Disease Patients

Association of CYP2C19*2/3 gene polymorphism with lung cancer in Moroccan population

Contact Info

Product

Resources

About